Glioblastomas (GBMs) contain transformed, self-maintaining, multipotent, tumour-initiating cancer stem cells, whose identification has radically changed our perspective on the physiology of these tumours. Currently, it is unknown whether multiple types of transformed precursors, which display alternative sets of the complement of properties of true cancer stem cells, can be found in a GBM. If different subsets of such cancer stem-like cells (CSCs) do exist, they might represent distinct cell targets, with a differential therapeutic importance, also depending on their characteristics and lineage relationship. Here, we report the presence of two types of CSCs within different regions of the same human GBM. Cytogenetic and molecular analysis shows that the two types of CSCs bear quite diverse tumorigenic potential and distinct genetic anomalies, and, yet, derive from common ancestor cells. This provides critical information to unravel the development of CSCs and the key molecular/genetic components underpinning tumorigenicity in human GBMs.
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We recently described the existence of tumourinitiating cells within human GBMs, which possess critical neural stem cell features and the ability, at the clonal level, to establish GBM phenocopies (Galli et al., 2004) . We now report that the distinct regions of the same GBM comprise diverse subpopulations of such cancer stem-like cells (CSCs). Strikingly, they share common ancestors, although being quite different, both at the functional and genetic levels.
All of the tumours used in this study were diagnosed as primary human GBMs. Specimens were obtained from either the very core of the tumour (avoiding necrotic tissue) or from at least 2 cm away from it. Although data from a representative sample (62-year-old male patient) are presented in detail, three specimens, yielding overlapping results, were investigated in our study (see Supplementary data). Using the neurosphere protocol, which isolates GBM CSCs, two stable GBM cell cultures were established from the periphery (p-GBM) and the core (c-GBM) specimens.
As expected by CSCs (Galli et al., 2004) , both p-and c-GBM cells were multipotent and, following cloning and differentiation, gave rise to a progeny expressing neuronal, astroglial and oligodendroglial antigens (table in Figure 1 ). Notwithstanding, their growth properties were extremely different. Under identical conditions, c-GBM cells established typical neurosphere cultures, whereas p-GBM cells grew exclusively as a monolayer (Figure 1a) . The latter behaviour suggests a more differentiated cell state and a concomitant, lesser CSC content in p-GBMs (Piccirillo et al., 2006) . Hence, we performed both clonogenic and growth kinetic analysis (Reynolds and Rietze, 2005; Vescovi et al., 2006) , providing an estimate of the candidate CSC contents in culture and of their ability to expand as a population. Clearly, c-GBM cells displayed a faster growth kinetics and a much higher clonogenic index (Figure 1b) , showing that their CSC content was larger than that in p-GBMs (Po0.01). On the contrary, expression of CD133 antigen, whose role as a GBM stem cell marker remains controversial (Singh et al., 2004; Beier et al., 2007; Gunther et al., 2008; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008) , was similar between c-and p-GBM (41.6 ± 5.3 and 44.8 ± 8.7 of total cell population, respectively). To conclusively define the nature of the two cell types, we investigated whether p-and c-GBM did possess different tumour-initiating ability. As expected, upon orthotopic transplantation of as high as 300 000 c-GBM cells/animal, GBM-like lesions (Supplementary Figure 3) arose in 100% of the immunodeficient scid recipients. Cells from these xenografts could be serially cloned and transplanted, as shown previously for bona fide CSCs (Galli et al., 2004) . Conversely, even transplantation of such a high number of p-GBM cells could never establish any tumour ( Figure 1c ). All animals transplanted with p-GBM survived for 15 months, with no sign of neurological alterations, whereas 100% of the mice receiving c-GBM cells died by 45-60 days after transplantation.
We then investigated the cytogenetic differences underlying such strikingly different properties. The main cytogenetic trait in GBM is represented by several chromosomal anomalies. Trisomy 7 and partial or complete monosomy 10 are found in 70% of GBMs, although partial loss of 9p correlates with later progression stages (64% of GBMs). Other aneuploidies, concerning chromosomes 13 and 22 (loss), 19 and 20 (gain) have been reported (http://cgap.nci.nih.gov/Chromosomes/Mitelman). We analysed the cytogenetic and molecular abnormalities in c-and p-GBM by quinacrine fluorescent (QFQ) banding and cosmid and genomic array fluorescence in situ hybridization, as well as by high-resolution single nucleotide polymorphisms array. When required, data were confirmed by microsatellite analysis. Results are summarized as a table in Figure 2 and as Supplementary Figure 1 and Table 1 . The modal hypodiploid number of chromosome per cell for both the cell lines was checked after several in vitro passages (9th-41st, p-GBM; 4th-51st, c-GBM), and remained constant at 44-45 in about 30% of cells, the remainder ranging from 35 to 90. In both c-and p-GBM cells, chromosomes 8, 16, 19, 22, X and Y were diploid and morphologically normal, whereas additional anomalies were identified (table in Figure 2 ; Supplementary Table  1) , some of which were not overlapping in the two cell types. In fact, a group of abnormalities was found in p-GBM, but not in c-GBM cells, and vice versa. In particular, deletion of 11q23-qter, with the break point located under the mixed lineage leukemia probe (http:// cgap.nci.nih.gov/Chromosomes/Mitelman; gift of M Rocchi, Bari, Italy) was identified in all of p-GBM cells. Conversely, deletion of 17p13-confirmed by fluorescence in situ hybridization using the cosmid probe TP53 (Oncor) and the a-satellite probe specific for centromere of chromosome 17-was specific to c-GBM cells (Supplementary Figure 1) . Notably, the deletion of 1p36 was shared by p-and c-GBM, but this was located on different chromosome 1 homologues in the two cell types (on the basis of another translocation involving the 1q arm and on the loss of heterozygosity data; Figure 2 and Supplementary Table 1) . Similarly, single nucleotide polymorphism array performed at early (6th and 8th) and late (34th and 43th) in vitro passages revealed that the monosomy of chromosome 18 involved distinct homologues in the two cell types, on the basis of the different haplotypes observed (Supplementary Table 1) .
On the other hand, monosomy of chromosome 10 showed the very same allelic composition in p-and c-GBM. Yet, microsatellite analysis of whole DNA tumour from embedded tissue of the original surgery specimen revealed heterozygosity for both chromosomes 10 and 18 in the primary GBM cells (data not shown). This suggests a particular mechanism separating the homologues 10 and 18, with a possible negative selection occurring early on against one of the chromosome 10 alleles or, alternatively, the existence of a positive selection, operating in vitro, in favour of one of the two chromosomes 10. Fluorescence in situ hybridization analysis on 4-mm thick histological sections, using 10 centromere-specific probes, displayed a single signal in all of the samples (more than 1000), with the exception of two cells, in a whole section, showing two signals (Supplementary Figure 2) . Finally, although trisomy 7 was observed in both cell types, both chromosomes 7 were involved in t(7;15) and t(5;7) translocations in p-GBM, whereas only t(7;15) was found in c-GBM (Figure 2 ). Regarding this specific trisomy, evidence of trisegmental uniparental disomy should be noted, as confirmed by comparison with normal tissue (data not shown). Additional anomalies acquired in vitro were also detected by single nucleotide polymorphism analysis (Supplementary Table 1 ). Hence, the significant differences in growth and tumorigenicity between p-and c-GBM cells from the same human GBM are associated with two distinct sets of genetic alterations, each occurring specifically in one cell type, but not the other, although c-and p-GBM cells do share a set of common alterations. Similar results have been obtained using two additional primary GBM samples (Supplementary  Figure 4) .
The cancer stem cell hypothesis holds that tumours, including GBMs, might be established, expanded and perpetuated by a small population of cells bearing stem cell properties and aberrant growth and tumour-initiating capability (Ailles and Weissman, 2007) .
We provide the first evidence that two CSC populations reside within distinct regions of the same human GBMs, which greatly differ in their growth properties and tumour-initiating ability. In fact, both p-and c-GBM cells possess key neural stem cell features, such as multipotency (Figure 1b) , clonogenic ability ( Figure 1b ) and extensive self-renewal, together with aberrant growth properties (Figure 1 ; Galli et al., 2004 ). Yet, both c-GBM cells expand much faster and bear a much higher clonogenic index than p-GBMs. This is indicative of a larger content of CSCs within the c-GBM pool that reflects a higher frequency of symmetric divisions generating two CSCs, rather than more mature cells in this pool (Reynolds and Rietze, 2005) . This is in full agreement with the observation that none of the mice receiving p-GBM developed tumours compared with 100% of those receiving c-GBM. Thus, although we cannot conclude that p-GBM lack tumorigenic potential entirely, it is clear that their tumour-initiating ability is vastly reduced compared with the c-GBM cells from the same surgery specimen.
Most important, these functional differences corresponded to intriguing, diverse patterns of karyotype and genotype alterations in p-versus c-GBM cells, which did confirm the existence of a lineage relationship between pand c-GBM that, however, was somewhat unexpected. A most educated hypothesis, would infer that the CSCs at the periphery of the tumour had migrated away from the core, thus being the descendants of core CSCs. Yet, although p-GBM cells do share common genetic aberrations with c-GBM, such as trisomy 7, monosomy 10, t(1;9)(q31;p13), t(7;15)(q32;q21-22), they display a specific set of chromosome and genomic alterations not observed in the latter and vice versa. Hence, c-and p-GBM derive from common ancestor cells upon accumulation of further aberrations, which led them to acquire different characteristics. At present, it is possible to draw speculations on the nature/identity of such ancestors. It would appear that these cells were scarce within the original specimen, as shown by our molecular and cytogenetic analysis of the primary tumour tissue. In addition, such cells might not have been positively selected by the neurosphere assay and might have simply been eliminated upon cell isolation. If this were true, the original mutations occurring in these ancestor cells would have apparently conferred a limited proliferation advantage. The latter would have been significantly augmented in their progeny, the c-and p-GBM cells, through the accumulation of additional, yet distinct sets of mutations, resulting in a much higher content of CSCs and higher tumorigenicity in c-GBM cells. These findings prompt an active search for such candidate ancestor cells within primary GBM surgery specimens, as this could shed light on the specific and critical aberration/mutation steps that must occur in neural cells for them to acquire bona fide cancer stem cell features and, particularly, tumourinitiating ability.
In conclusion, our study describes a system, heretofore unavailable, by which stem-like GBM cells, which specifically differ in their ability to multiply and tumourinitiating capacity, are derived from the very same patient and surgery specimen.
By this tool, it should be possible to perform differential screening assays of the genetic mutations and molecular alterations that underpin the malignant GBM phenotype in humans while, at the same time, eliminating the 'background noise' caused by the use of cells derived from different patients, age, areas and tumour heterogeneity.
The possibility to correlate a malignant phenotype with a defined genetic profile could lead to the identification of candidate molecular mechanism/mutations that play a key role in the tumour-initiating activity of GBM cells.
Conflict of interest
The authors declare no conflict of interest.
